See What HealthDay Can Do For You
Contact Us

Intensive BP Control Lacks Benefit in Chronic Kidney Disease

Findings based on large, post-hoc analysis of the Systolic Blood Pressure Intervention Trial

blood pressure cuff

FRIDAY, Nov. 17, 2017 (HealthDay News) -- Intensive blood pressure (BP) control may provide no benefit and may even be harmful for patients with moderate-to-advanced chronic kidney disease, according to a study published online Oct. 16 in the Journal of Internal Medicine.

Yoshitsugu Obi, Ph.D., from the University of California Irvine Medical Center, and colleagues conducted post-hoc analysis of the Systolic Blood Pressure Intervention Trial to determine the risk-benefit profile of intensive BP control across estimated glomerular filtration rate (eGFR) levels.

The researchers found that the cardiovascular benefit from intensive treatment was diminished with lower eGFR (P interaction = 0.019), while eGFR did not alter the adverse effect on acute kidney injury (AKI; P interaction = 0.179). For the 891 participants with eGFR <45 mL/min/1.73 m2, intensive treatment did not reduce the cardiovascular outcome (hazard ratio [HR], 0.92; 95 percent confidence interval, 0.62 to 1.38), while it increased AKI (HR, 1.73; 95 percent confidence interval, 1.12 to 2.66).

"Intensive BP control may provide little or no benefit and even be harmful for patients with moderate-to-advanced chronic kidney disease," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.